Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 5/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27756629 | 0.98 | NOTUM (0.51) | NOTUMKDM4EHSD17B3SLC22A12L3MBTL1 | |
| SCHEMBL5026715 | 0.83 | NOTUM (0.51) | NOTUMKDM4EHSD17B3SLC22A12L3MBTL1 | |
| SCHEMBL11354049 | 0.82 | NOTUM (0.47) | NOTUMKDM4EHSD17B3SLC22A12L3MBTL1 | |
| SCHEMBL15524285 | 0.81 | NOTUM (0.73) | NOTUMKDM4EL3MBTL1LMNAHPGD | |
| Acetic Acid SCHEMBL5028762 | 0.81 | NOTUM (0.54) | NOTUMKDM4EHSD17B3SLC22A12L3MBTL1 | |
| SCHEMBL11193164 | 0.80 | NOTUM (0.49) | NOTUMKDM4EHSD17B3SLC22A12L3MBTL1 | |
| SCHEMBL4724326 | 0.79 | NOTUM (0.51) | NOTUMKDM4EHSD17B3SLC22A12L3MBTL1 | |
| SCHEMBL11407839 | 0.79 | BCHE (0.54) | NOTUMKDM4EHSD17B3SLC22A12L3MBTL1 | |
| SCHEMBL28542746 | 0.78 | NOTUM (0.46) | NOTUMKDM4EHSD17B3SLC22A12L3MBTL1 | |
| SCHEMBL28307229 | 0.77 | BCHE (0.58) | NOTUMKDM4EL3MBTL1SMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655368-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2013-10-30 | — | — | EP | claimed |
| WO-2012087520-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2012-06-28 | — | — | WO | claimed |
| EP-1981883-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | claimed |
| CN-101119980-A | Novel benzothiazole carboxamides | ASTRAZENECA AB (SE) | 2008-02-06 | — | — | CN | claimed |
| WO-2007086800-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | claimed |
| EP-4321504-B1 | PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF | XIAMEN SINOPEG BIOTECH CO LTD (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20240197633-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| US-20240180951-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-06-06 | — | — | US | disclosed |
| WO-2024041460-A1 | NOVEL NLRP3 INFLAMMASOME INHIBITORS | HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD (CN) | 2024-02-29 | — | — | WO | disclosed |
| EP-4321504-A1 | PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| EP-4321503-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED THEREBY, PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME, PREPARATION THEREOF, AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023186020-A1 | NLRP3 INFLAMMASOME INHIBITORS | HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD (CN) | 2023-10-05 | — | — | WO | disclosed |
| EP-1677791-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| CN-1726033-A | Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds | PHARMACIA & UPJOHN CO LLC (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1684962-A | Indazoles, benzothiazoles, and benzisothiazoles, and preparation and use thereof | MEMORY PHARM CORP (US) | 2005-10-19 | — | — | CN | disclosed |
| WO-2005044793-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | WO | disclosed |
| EP-0938477-A4 | BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC (US) | 1999-12-29 | — | — | EP | disclosed |
| US-5952328-A | MAY BE USED TO ALLEVIATE, MEDIATE, REDUCE AND/OR PREVENT DISORDERS WHICH ARE ASSOCIATED WITH ABNORMAL AND/OR ABERRANT ACTIVITY OF CYSTEINE PROTEASES AND/OR SERINE PROTEASES | CEPHALON, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0938477-A1 | BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998021186-A1 | BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180951-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | LIPG, PHOSPHO1, LDLR | NOTUM 4372/4885KDM4E 2140/4885HSD17B3 4130/4885 |
| US-20240197633-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | LIPG, LDLR, LIPA | NOTUM 3408/4885KDM4E 1858/4885HSD17B3 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.